Clinical Trial of Rapamycin and Irinotecan in Pediatric Patients With Refractory Solid Tumors

Inclusion Criteria:

* Age \>= 1 year old and =\< 21 years old;
* Refractory solid tumors, histologically proven at diagnosis (no additional biopsy needs to be performed for the purpose of the study);
* Relapsed or refractory solid tumors after standard treatment or phase II, III-IV clinical trials treatment have failed;
* Karnofsky or Lansky status \>= 70%;
* Life expectancy \>= 8 weeks;
* No chemotherapy / radiotherapy within 4 weeks before entry into the study;
* Adequate biological parameters :

  * Absolute neutrophil count \>= 1.0 x 109/L;
  * Platelet count \>= 100 x 109/L;
  * Hemoglobin \>= 8 mg/dL;
  * Total bilirubine =\< 1.5 ULN;
  * Transaminases =\< 2.5 ULN (=\< 5 ULN in case of liver metastases);
  * Creatinine clearance (Cockroft) \>= 70 mL/min/1.73 m2;
  * Normal coagulation profile with prothrombin \>= 70%, TCA =\< 35 and fibrinogen \>= 2 g/L;
* Patients with 1 to 3 previous therapeutic lines are eligible;
* No current grade \>= 2 organ toxicity based on NCI-CTCAE version 3.0;
* All patients with reproductive potential must have an effective method of birth control while on study;
* Negative pregnancy test in females when indicated;
* Informed written consent signed by patients or their parents or legal guardians;
* Patient who was informed of the results of prior medical consultation;
* Patient having a social insurance.

Exclusion Criteria:

* Patient with a constitutional anomaly of coagulation and/or of hemostasis (type hemophilia, von Willebrand disease, congenital clotting factor deficit, platelet disorder), exposing them to increased risk of bleeding;
* Pre-treatment with a mTOR inhibitor;
* Other simultaneous malignancy;
* Concurrent administration of any other anti-tumour therapy;
* Known hypersensitivity or contraindication to study drugs or ingredients;
* Severe concomitant disease (e.g. infection disease);
* Patient unable for medical follow-up;
* Pregnancy and/or lactation;
* Patient included in another clinical drug trial;
* Patient taking drugs interfering with pharmacology of rapamycin and/or irinotecan (e.g. drugs interfering with CYP3A4);
* Patient under judicial protection.